companies / hephaistos-pharma-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 2,700,0002.7M | ○ |
|---|---|---|
| founded | null | |
| hq | Orsay | |
| industry | unknown | |
| stage | null |
Hephaistos-Pharma develops a third-generation TLR4-agonist small molecule for cancer immunotherapy, with lead candidate HEPHA440 reprogramming suppressive myeloid cells and activating immune responses. It targets oncology patients with myeloid-rich tumors resistant to current immunotherapies. It aims to turn immunologically cold tumors hot via a dual innate-and-adaptive mechanism.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2023-07-01 | grant | 2,700,0002.7M | null | ○ |
PHP 8.2.29, WordPress 6.9.4, Apache HTTP Server, Google Maps, FitVids.JS 4.27.4, jQuery Migrate 3.4.1, CookieYes 3.5.0, Varnish 6.3, Zepto, MySQL, jquery 3., apache
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |